COMPANY
History
Since our founding in 2024, we have been setting a new standard in drug design
with our innovative AI×MD technology.
Our Growth Journey
Since its founding in 2024, Atomatrix has rapidly grown by pioneering next-generation drug design technologies that integrate AI and molecular dynamics (MD).
From being selected for government projects and collaborating with major pharmaceutical companies to developing a SaaS platform, we are establishing a new standard in drug design based on innovative technology and scientific validation.
2024
Foundation & Launch
2024.05.16
Atomatrix Inc. founded
Officially launched to pioneer AI×MD-driven innovation in drug design
Officially launched to pioneer AI×MD-driven innovation in drug design
2024.09
Technical service contract signed with Flomedi Co.
First commercial project validating the practical value of our technology
First commercial project validating the practical value of our technology
2024.05-12
2 Confidential Disclosure Agreements (CDA) and 1 Memorandum of Understanding (MOU) signed
2025
Validation & Growth
2025.01
Establishment of Corporate Research Center
Strengthened systematic R&D capacity and infrastructure
Strengthened systematic R&D capacity and infrastructure
2025.02
Participation in 2025 Biophysical Society Annual Meeting (BPS2025, USA)
Shared technological advances and built global academic networks
Shared technological advances and built global academic networks
2025.04
Selected for Government Startup Support Program (Initial Startup Package)
Public recognition of technical excellence and business potential
Public recognition of technical excellence and business potential
2025.05
Selected for new tenant recruitment at Pangyo Startup Zone
Expanded business base at Korea’s central biotech cluster
Expanded business base at Korea’s central biotech cluster
2025.06
Seed investment acquired
2025.06
Selected as Chemical Science Hot Article
2025.07
Selected for IBK Changgong H2 Innovation Startup Program (Second Half)
2025.08
Selected for TIPS (Tech Incubator Program for Startup) Project
2025.09
Selected for Seoul Bio Hub-Daewon Pharmaceutical Open Innovation Program
2025.01-10
7 Confidential Disclosure Agreements (CDA) and 1 Memorandum of Understanding (MOU) signed
2026
Global Scale
2026.06
Official launch of SaaS-based CADD platform
Global platform service begins, enabling researchers worldwide to utilize AI×MD technology in a cloud environment
Global platform service begins, enabling researchers worldwide to utilize AI×MD technology in a cloud environment